Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,155 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1.
Ackerman P, Thompson M, Molina JM, Aberg J, Cassetti I, Kozal M, Castagna A, Martins M, Ramgopal M, Sprinz E, Treviño-Pérez S, Streinu-Cercel A, Latiff GH, Pialoux G, Kumar PN, Wang M, Chabria S, Pierce A, Llamoso C, Lataillade M. Ackerman P, et al. Among authors: castagna a. AIDS. 2021 Jun 1;35(7):1061-1072. doi: 10.1097/QAD.0000000000002851. AIDS. 2021. PMID: 33946085 Free PMC article.
Response to combination antiretroviral therapy: variation by age.
Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group; Sabin CA, Smith CJ, d'Arminio Monforte A, Battegay M, Gabiano C, Galli L, Geelen S, Gibb D, Guiguet M, Judd A, Leport C, Dabis F, Pantazis N, Porter K, Raffi F, Thorne C, Torti C, Walker S, Warszawski J, Wintergerst U, Chene G, Lundgren J. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group, et al. AIDS. 2008 Jul 31;22(12):1463-73. doi: 10.1097/QAD.0b013e3282f88d02. AIDS. 2008. PMID: 18614870
Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience.
Nozza S, Galli L, Visco F, Soria A, Canducci F, Salpietro S, Gianotti N, Bigoloni A, Torre LD, Tambussi G, Lazzarin A, Castagna A. Nozza S, et al. Among authors: castagna a. AIDS. 2010 Mar 27;24(6):924-8. doi: 10.1097/QAD.0b013e3283372d76. AIDS. 2010. PMID: 20154578
No pol mutation is associated independently with the lack of immune recovery in patients infected with HIV and failing antiretroviral therapy.
Gianotti N, Galli L, Zazzi M, Ghisetti V, Bonora S, Micheli V, Meraviglia P, Corsi P, Bruzzone B, Menzo S, Di Giambenedetto S, De Luca A, Filice G, Penco G, Castagna A; ARCA database initiative. Gianotti N, et al. Among authors: castagna a. J Med Virol. 2011 Mar;83(3):391-8. doi: 10.1002/jmv.21989. J Med Virol. 2011. PMID: 21264858
Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count.
Marchetti G, Cozzi-Lepri A, Merlini E, Bellistrì GM, Castagna A, Galli M, Verucchi G, Antinori A, Costantini A, Giacometti A, di Caro A, D'arminio Monforte A; ICONA Foundation Study Group. Marchetti G, et al. Among authors: castagna a. AIDS. 2011 Jul 17;25(11):1385-94. doi: 10.1097/QAD.0b013e3283471d10. AIDS. 2011. PMID: 21505312
Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy.
Pavie J, Porcher R, Torti C, Medrano J, Castagna A, Valin N, Rusconi S, Ammassari A, Ghosn J, Delaugerre C, Molina JM; NEAT Unboosted Atazanavir Cohort Study Group. Pavie J, et al. Among authors: castagna a. J Antimicrob Chemother. 2011 Oct;66(10):2372-8. doi: 10.1093/jac/dkr316. Epub 2011 Aug 5. J Antimicrob Chemother. 2011. PMID: 21821627 Free article.
1,155 results